Tyme Technologies

January 31, 2018

Trial to Assess Whether Tyme Therapy or Monitoring Is Better for Prostate Cancer Patients

News

A clinical trial will assess whether Tyme Technologies’ SM-88 is a better treatment option than active surveillance for prostate cancer patients who have not had surgery, radiation, or chemotherapy. Tyme has asked an ... Read more

September 14, 2017

Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients

News

Tyme Technologies‘ SM-88 reduced the levels of circulating cancer cells — an indicator of metastatic disease — in all prostate cancer patients treated in an ongoing Phase 2 trial, according ... Read more

June 9, 2017

TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data

News

Preliminary results from a Phase 1b/2 clinical trial evaluating the safety, pharmacokinetics, and efficacy of TYME-88 (SM-88) to treat recurrent, non-metastatic prostate cancer found that all eight enrolled patients, who did not ... Read more

December 13, 2016December 13, 2016

Tyme Completes Enrollment in Phase 1b of Prostate Cancer Study for New Therapy Candidate

News

Tyme Technologies has completed enrolling particpants in the Phase 1b portion of the open-label Phase 1b/2 clinical trial evaluating its lead investigational drug candidate SM-88 in non-metastatic prostate cancer patients with rising ... Read more